Status:

UNKNOWN

Pancreatic Stone Protein (PSP) in Pregnant Women

Lead Sponsor:

Nicole Ochsenbein

Collaborating Sponsors:

University of Zurich

Conditions:

Pregnancy

HELLP Syndrome

Eligibility:

FEMALE

18+ years

Brief Summary

This prospective, single centred cohort study evaluates the physiological course of the potentially novel biomarker PSP in pregnant women as well as its predictive role in the development of inflammat...

Detailed Description

Pregnant women feature a complex immunological condition caused by pregnancy itself and hence women present with an increased susceptibility to some infectious and non-infectious inflammatory diseases...

Eligibility Criteria

Inclusion

  • Age \> 18 years
  • Healthy women with single pregnancy
  • Women with PPROM, AIS, preeclampsia, or HELLP syndrome
  • Patients able to provide informed consent

Exclusion

  • Viral (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) or confirmed bacterial infections

Key Trial Info

Start Date :

September 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2019

Estimated Enrollment :

486 Patients enrolled

Trial Details

Trial ID

NCT02247297

Start Date

September 1 2014

End Date

September 1 2019

Last Update

November 26 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Zurich

Zurich, Switzerland, 8091

Pancreatic Stone Protein (PSP) in Pregnant Women | DecenTrialz